| Type of support |
Approvals 2001-2023 (US$)(26 Sep 2018) |
Commitments 2001-2023 (US$)(26 Sep 2018) |
Disbursements 2000-2018 (US$)(26 Sep 2018) |
% Disbursed(26 Sep 2018) |
2001 |
2002 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
|---|
|
| Total |
$108,868,165 |
$120,977,165 |
$110,925,358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash support (CASHSUPP) |
$170,000 |
$195,000 |
$170,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$7,468,586 |
$7,468,586 |
$7,427,786 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV (NVS) |
$2,540,500 |
$6,678,000 |
$2,536,040 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$240,095 |
$240,095 |
$240,095 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC (NVS) |
$6,111,500 |
$6,111,500 |
$6,098,700 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC - Op costs (OPC) |
$385,626 |
$385,626 |
$385,626 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$1,529,848 |
$1,529,848 |
$1,529,848 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$344,935 |
$570,435 |
$402,904 |
117% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$948,925 |
$948,925 |
$948,925 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$839,759 |
$839,759 |
$37,259 |
4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles (NVS) |
$504,000 |
$890,000 |
$340,268 |
68% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Rubella (NVS) |
$3,785,235 |
$3,785,235 |
$3,785,235 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR - Operational costs (OPC) |
$3,407,312 |
$3,407,312 |
$3,407,312 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$28,783,773 |
$29,533,773 |
$28,959,313 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$40,067,552 |
$44,903,552 |
$43,445,968 |
108% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$121,928 |
$121,928 |
$121,928 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$9,191,075 |
$10,940,075 |
$9,372,785 |
102% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCV - Outbreak op. costs (OPC) |
$202,150 |
$202,150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCV Outbreak (NVS) |
$510,000 |
$510,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$1,715,366 |
$1,715,366 |
$1,715,366 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format